Methods of treating mental diseases, inflammation and pain

Details Methods of treating mental diseases, inflammation and pain Methods of treating mental diseases, inflammation and pain

1999-04-07

2003-02-25

Criares, Theodore J. (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S460000

Reexamination Certificate

active

06525090

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to methods and compositions for treating disorders such as mental diseases, inflammation and pain. More particularly, the invention relates to methods for treating such disorders by administering a therapeutically effective level of an anandamide amidohydrolase inhibitor.
BACKGROUND OF THE INVENTION
Anandamide (N-arachidonoylethanolamine) is thought to act as an endogenous cannabinoid neurotransmitter in vertebrate nervous systems. It binds to and activates cannabinoid receptors and simulates many distinctive effects typical of plant-derived or synthetic cannabinoid drugs.
Biochemical evidence indicates that anandamide is produced in and released from neurons in an activity-dependent manner. Further, as expected of a signalling molecule, anandamide is short-lived: its life-span is limited by uptake into neural cells and by enzymatic hydrolysis. Anandamide hydrolysis is catalyzed by the enzyme anandamide amidohydrolase, which converts anandamide to yield two inactive metabolites, arachidonate and ethanolamine. This reaction is illustrated by the following:
Anandamide amidohydrolase is likely to play an important role in the physiological degradation of anandamide. Three lines of evidence support this possibility. First, anandamide amidohydrolase is highly selective. Second, anandamide amidohydrolase is discretely distributed in the central nervous system, where its localization parallels that of cannabinoid receptors. Third, a protease inhibitor that blocks anandamide amidohydrolase non-selectively, phenylmethylsulphonylfluoride, extends the actions of anandamide.
Therefore, inhibition of anandamide amidohydrolase to increase the accumulation of anandamide at its sites of action is desirable as a potential therapeutic approach for the treatment or prevention of disorders such as mental diseases, inflammation and pain, including treatment or prevention of schizophrenia, mood disorders, anorexia, multiple sclerosis, spasticity and glaucoma. Despite these potential applications, no potent and selective inhibitors of anandamide amidohydrolase have been identified as yet.
The anandamide amidohydrolase inhibitors useful in the present invention comprise haloenol lactones. The preferred haloenol lactones are compounds of the formula:
wherein R is hydrogen, R
1
is a halogen, and R
2
is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals. A most preferred haloenol lactone is E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one which has the following formula:
The synthesis of this compound and the identification of its ability to inhibit an enzyme which is unrelated to anandamide amidohydrolase, i.e., the cardiac calcium-independent phospholipase A
2
, have been described in the following patents and publications: Hazen, et al.,
J. Biol. Chem
. 266, 7227-7232 (1991); Weiss, et al., U.S. Pat. No. 5,208,244; and Balsinde, et al.,
Proc. Natl. Acad. Sci. U.S.A
. 92, 8527-8531 (1995).
SUMMARY OF THE INVENTION
The invention comprises methods of treating or preventing disorders such as mental diseases, inflammation and pain, including schizophrenia, mood disorders, anorexia, multiple sclerosis, spasticity and glaucoma by administering a therapeutically effective level of an anandamide amidohydrolase inhibitor. The preferred anandamide amidohydrolase inhibitors comprise haloenol lactones. The preferred haloenol lactones are compounds of the formula:
wherein R is hydrogen, R
1
is a halogen, and R
2
is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, and derivatives and mixtures thereof. The most preferred anandamide amidohydrolase inhibitors comprise E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one, derivatives of this compound, and mixtures thereof.
The present invention further comprises methods of inhibiting anandamide amidohydrolase by administering a therapeutically effective amount of a haloenol lactone. The preferred haloenol lactones are compounds of the formula:
wherein R is hydrogen, R
1
is a halogen, and R
2
is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, derivatives of these compounds and mixtures thereof. The most preferred anandamide amidohydrolase inhibitors comprise E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one.
The invention further comprises pharmaceutical compositions comprising anandamide amidohydrolase inhibitors for treating mental diseases, inflammation and pain, such as schizophrenia, mood disorders, anorexia, multiple sclerosis, spasticity and glaucoma. The preferred compositions comprise a haloenol lactone at a therapeutically effective level to inhibit anandamide amidohydrolase.


REFERENCES:
patent: 4602006 (1986-07-01), Krantz et al.
patent: 5001242 (1991-03-01), Kuekenhoehner et al.
patent: 5208244 (1993-05-01), Weiss
patent: 5286746 (1994-02-01), Poss
patent: 5294724 (1994-03-01), Jendralla et al.
patent: 5308864 (1994-05-01), Lewis et al.
patent: 5385932 (1995-01-01), Vickers
patent: 5447957 (1995-09-01), Adams et al.
patent: 5470882 (1995-11-01), Dixon et al.
patent: 5925672 (1999-07-01), Piomelli et al.
Hazen et al.,Suicide Inhibition of Canine Myocardial Cytosolic Calcium-independent Phospholipase A2, Journal of Biological Chemistry, The, Col. 226, No. 11, pp. 7227-7232 (Apr. 15, 1991).
Fontana et al.,Analysis of Anandamide, an Endogenous Cannabinoid Substance, and of Other Natural N-Acylethanolamines, Prostaglandins Leukotrienes and Essential Fatty Acids, 53, pp. 301-308 (1995).
Desarnaud et al.,Anandamide Amidohydrolase Activity in Rat Brain Microsomes, The Journal of Biological Chemistry, vol. 270, No. 11, pp. 6030-6035 (Mar. 17, 1995).
Balsinde et al.,Inhibition of calcium-independent phospholipase A2prevents arachidonic acid incorporation and phospholipid remodeling in P388D1macrophages, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 8527-8531 (Aug., 1995).
Cadas et al.,Biosynthesis of an Endogenous Cannabinoid Precursor in Neurons and its Control by Calcium and cAMP, The Journal of Neuroscience, 16(12):3934-3942 (Jun. 15, 1996).
Beltramo et al.,Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one, FEBS Letters 403, pp. 263-267 (1997).
Remington,Pharmaceutical Sciences, Arthur Osol. Ed., 16th Ed., Mack Publishing Co. (1980).

Affiliated with

Also associated with

Rating

Methods of treating mental diseases, inflammation and pain does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating mental diseases, inflammation and pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating mental diseases, inflammation and pain will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3141841